John [last name not provided]'s questions to Evolus Inc (EOLS) leadership • Q3 2024
Question
An analyst named John, on behalf of Serge Belanger at Needham & Co., asked for details on the early access program for Estyme in Europe and whether it would generate significant revenue contributions before the broader 2025 launch.
Answer
CFO Sandra Beaver clarified that the early experience trials for Estyme in Europe are modest in terms of investment and will not have a material impact on the company's current operating expense outlook. She noted that the bulk of launch-related costs are planned for the U.S. launch in 2025.